TREATMENT OF GENOTYPE 2
|
|
- Theodore Brian Wilson
- 6 years ago
- Views:
Transcription
1 Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead, Janssen Grant/Research Support: AbbVie Pharmaceuticals, Bristol-Myers Squibb,, Gilead, Janssen, Merck Speakers Bureau: AbbVie Pharmaceuticals, Gilead TREATMENT OF GENOTYPE 2 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 1
2 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve N=499 Stratified by HCV genotype, HCV RNA, and cirrhosis Randomized 1:1 Study Week SOF + RBV*, n=256 SVR12 *RBV dose 12 mg/d PEG-IFN + RBV (SOC), n=243 SVR12 mg/d for PEG-IFN+RBV No response guided therapy HCV RNA analyzed by COBAS TaqMan HCV Test v2. HPS, with LLOQ of 25 IU/mL Lawitz E, et al. N Engl J Med. 213; 368: FISSION SVR 12 for Genotype 2: TREATMENT NAIVE SOF/RBV 12 wks PEG/RBV 24 wks Overall No cirrhosis Cirrhosis Lawitz E, et al. N Engl J Med. 213; 368: ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 2
3 FUSION STUDY: Genotype 2 and 3 Treatment Experienced HCV GT 2 and GT 3 Treatmentexperienced N=21 Stratified by HCV genotype and cirrhosis Randomized 1:1 Study Week SVR12 SOF + RBV, n=13 Placebo SVR12 SOF + RBV, n=98 SOF dose mg QD; RBV dose 12 mg/d No response guided therapy HCV RNA analyzed by COBAS TaqMan HCV Test v2. HPS, with LLOQ of 25 IU/mL Nelson DR, et al. EASL 213. Amsterdam, The Netherlands. Oral #6 Jacobson IM, et al. N Engl J Med. 213 Apr 23 FUSION SVR 12 for Genotype 2: TREATMENT EXPERIENCED SOF/RBV 12 wks 96 SOF/RBV 16 wks 78 2 Overall No cirrhosis Cirrhosis Jacobson et al. NEJM 213,368: ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 3
4 LONESTAR-2: Sofosbuvir + P/R for 12 Wks in Treatment-Exp d GT2/3 HCV Pts Single-arm trial of pts with treatment failure on P/R Approximately 5% with compensated cirrhosis Wk 12 Pts with GT2 or GT3 HCV and previous treatment failure with P/R (N = 47) SOF mg QD + PegIFN wkly + RBV mg or 12 mg SVR12 (%) Lawitz E, et al. AASLD 213. Abstract LB-4. 2 n/n = 22/23 13/14 9/9 GT2 All GT2 F4 GT2 F-3 Treatment of Naïve Genotype 2 with Sofosbuvir + Daclatasvir (NS5A): 24 weeks SVR (%) GT 1 Naive GT 1 Experienced GT 2 GT 3 GT 3: 1 lost to f/u 1 viral failure Sulkowski M et al. N Engl J Med. 214;37: ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 4
5 NEW THERAPIES ON THE HORIZON FOR GENOTYPE 2 Sofosbuvir + Velpatasvir for G2 Sofosbuvir (SOF) 1,2 Potent antiviral activity against HCV GT 1 6 Once-daily, oral, -mg tablet SOF Nucleotide polymerase inhibitor Velpatasvir 3-5 Picomolar potency against HCV GT 1 6 PK supports once-daily dosing GS-5816 NS5A inhibitor SOF + Velpatasvir 6 Treatment for resulted in high SVR in treatment-naïve patients with HCV GT 1 6 without cirrhosis SOF + GS Jacobson IM, et al. New Engl J Med 213;368: ; 2. Lawitz E, et al. New Engl J Med 213;368: ; 3. Cheng G, et al. EASL 213, poster 1191; 4. German P, et al. EASL 213, poster 1195; 5. Lawitz E, et al. EASL 213, poster Everson G, et al. EASL 214, oral presentation. 3 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 5
6 Astral 1: Velpatasvir (NS5A) + SOF for - Genotype 2, 4, 5 and 6 97 SVR 2 14/14 116/116 41/41 34/35 GT 2 GT 4 GT 5 GT 6 Feld et al. AASLD 215 Abstract LB-2 SVR Astral 2: Velpatasvir (NS5A) + SOF for in Genotype 2 14% cirrhosis /134 SOF/VEL 14% PEG/RBV treatment experienced 1 patient in the SOF/VEL took 1 dose and stopped due to 124/132 dizzyness SOF/RBV Sulkowski et al. AASLD 215 Abstract 25 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 6
7 HCV NS3/4A inhibitor mg once daily, oral HCV NS5A inhibitor 5 mg once daily, oral Grazoprevir (MK-5172) Elbasvir (MK-8742) Broad in vitro activity against most HCV genotypes 1-3 Retains in vitro activity against many clinically relevant RAVs 1-3 All-oral, once-daily regimen 1. Summa V, et al. Antimicrobial Agent Chemother. 212:56; Coburn CA, et al. ChemMedChem. 213:8; Harper S, et al. ACS Med Chem Lett. 212:Mar 2; 3(4): C-Crest: Grazoprevir/MK-3682 (NS5B) + either elbasvir or MK-88 (NS5A) for SVR 2 GZR/EBR/ mg GZR/EBR/ mg GZR/88/ mg GZR/88/ mg GT 1 GT 2 GT 3 Gane et al. AASLD 215 Abstract LB-15 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 7
8 Recommendations for Genotype 2 Treatment Population Recommended Regimen Duration Treatment naïve noncirrhosis RBV -12 mg/day Sofosbuvir mg + Sofosbuvir mg + Treatment naïve cirrhosis Ribavirin -12 mg/day 16 weeks Treatment naïve (noncirrhosis and cirrhosis Treatment experienced (PEG-IFN/RBV) Treatment experienced (PEG-IFN/RBV) Treatment experienced (Sofosbuvir + RBV) Daclatasvir mg + sofosbuvir mg Sofosbuvir mg + Ribavirin -12 mg/day Sofosbuvir mg + Ribavirin -12 mg/day + PEG-IFN Dacalatasvir mg + sofosbuvir + RBV accessed 11/25/ weeks 24 weeks THERAPY FOR GENOTYPE 3 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 8
9 GT 3 Is Associated With a Significantly Higher Risk of Cirrhosis and HCC vs GT 1 VA HCV Clinical Case Registry (2-29) 88,348 patients with genotype 1 (%) 13,77 genotype 2 (12%) 8,337 genotype 3 (7.5%) Mean follow-up 5.4 years After adjustment for demographic, clinical and antiviral treatment factors, comparison between genotypes 3 and 1 Hazard Ratio Confidence Interval Cirrhosis HCC Conclusion: GT 3 is associated with a significantly higher risk of cirrhosis and HCC vs GT 1, independent of age, diabetes, BMI or antiviral treatment Kanwal F et al, Hepatology 214;:98-15 Treatment of Genotype 3 Fission Naive SOF/RBV 12 wks PEG/RBV 24 wks Fusion Treatment Experienced SOF/RBV 12 wks SOF/RBV 16 wks Overall No Cirrhosis cirrhosis Overall No Cirrhosis cirrhosis Lawitz E, et al. N Engl J Med. 213; 368: Jacobson et al. NEJM 213,368: ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 9
10 VALENCE: Sofosbuvir and Ribavirin Week GT 3 Sofosbuvir + RBV (n = 25) SVR12 Original Study Protocol: Placebo versus treatment for GT 2 and 3. Amended Protocol: GT3 treatment extended from 12 to 24 weeks; Placebo arm offered alternative treatment Drug Dosing Sofosbuvir mg once daily Ribavirin (weight-based and divided bid): mg/day if < 75 kg or 12 mg/day if 75 kg Zeuzem S, et al. NEJM 214;37: VALENCE: 24 Wks SOF + RBV in GT 3 Patients SVR12 (%) 2 212/25 86/92 12/13 87/ 27/45 Overall Naive, Naive, Experienced, Experienced, Non-cirrhotic Cirrhotic Non-cirrhotic Cirrhotic Extending treatment duration to 24 weeks did not significantly increase the incidence of AEs Zeuzem S, et al. NEJM 214;37: ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 1
11 Impact of Duration on Efficacy of SOF in Treatment-Experienced GT3 Pts 87 FUSION: 12 wks of SOF/RBV FUSION: 16 wks of SOF/RBV VALENCE: 24 wks of SOF/RBV SVR12 (%) n/n = 14/ 38 25/ No Cirrhosis 87/ 19 5/ 26 14/ 23 Cirrhosis 27/ 45 Genotype 3 Jacobson IM, et al. N Engl J Med. 213;368: Zeuzem S, et al. N Engl J Med. 214 Genotype 3: ALLY-3 Study Design Treatment-naive N = 11 Treatment-experienced N = 51 DCV mg + SOF mg QD DCV mg + SOF mg QD Follow-up Day 1 Week 12 Week 24 Week 36 Primary endpoint: SVR12 SVR12 Eligible patients Age 18 years with chronic GT 3 infection and HCV RNA 1, IU/mL Treatment-naive or -experienced (prior treatment failures), including patients with cirrhosis Those who received prior treatment with NS5A inhibitors were excluded Nelson et al. Hepatology 215; 61: ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 11
12 DCV/SOF for GT 3: SVR12 in Treatment-naïve and Treatmentexperienced patients Treated for 12 Weeks (ALLY-3) 9 86 SVR12 (%) 2 91/11 44/51 Treatment-naive Treatment-experienced Nelson DR, Hepatology 215; 61: SVR12 in Patients With and Without Cirrhosis Treated for 12 Weeks (ALLY-3) Overall Tx-naive Tx-experienced SVR12 (%) No Yes No Yes No Yes Cirrhosis Nelson DR, Hepatology 215; 61: ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 12
13 Sofosbuvir plus Daclatasvir with and without ribavirin in genotype 3: European Experience SVR Interim analysis of 82 patients in cohort of SOF/DCV SOF/DCV/RBV Overall Cirrhosis Treatment duration: 24 weeks Includes: Cirrhotics Post-OLT Welzel et al. AASLD 215 Abstract 37 SVR Daclatasvir/Sofosbuvir + RBV for genotype 3 F3 and F4 patients: The French Compassionate Study 96 F3 Results 81 2 DCV/SOF DCV/SOF/RBV 12 week 24 week Hezode et al. AASLD 215. Abstract 26 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 13
14 Daclatasvir/Sofosbuvir + RBV for genotype 3 F3 and F4 patients: The French Compassionate Study F4 Results SVR 2 DCV/SOF 4/4 DCV/SOF/RBV 12 week 24 week Hezode et al. AASLD 215. Abstract 26 Daclatasvir/Sofosbuvir + RBV for genotype 3 F3 and F4 patients: The French Compassionate Study Results by Childs Class SVR 2 33 DCV/SOF DCV/SOF/RBV Childs A Childs B Hezode et al. AASLD 215. Abstract 26 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 14
15 ALLY 3+ :DCV + SOF + RBV in GT 3 and advanced fibrosis and cirrhosis SVR 2 2 N=24 N=26 Overall 12 week 16 week F 3 F 4 TE cirrhosis 12 wk 16 wk Leroy et al. AASLD 215 Abstract LB-3 SOF/LDV with or without RBV for G3 16 patients, open label 82 Naïve: 2% cirrhosis i 64 2 TE: 44% cirrhosis 12 week treatment Gane et al. Gastro 215;149: ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 15
16 SOF+PEG/RBV x 12 Wks vs SOF+RBV x 24 Weeks: SVR12 in GT 3 Patients By Subgroup (BOSON Study) SOF + RBV 16 weeks SOF + RBV 24 weeks SOF + PEG/RBV SVR12 (%) Foster et al., Gastro 215; 149: /112 83/ 1/ TN No no Cirrhosis cirrhosis TN Cirrhosis cirrhosis TE No no Cirrhosis cirrhosis TE Cirrhosis cirrhosis Treatment Naïve Treatment Experienced 3 35 NEW THERAPIES ON THE HORIZON FOR GENOTYPE 3 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 16
17 Study Design ASTRAL-3 Week n=25 SOF/VEL SVR12 n=25 SOF + RBV SVR12 Open-label, active-comparator trial Broad inclusion criteria 1:1 randomization to SOF/VEL or SOF + RBV Stratified by prior treatment (TN/TE) and cirrhosis (presence/absence) Conducted at 76 sites in US, Canada, UK, Germany, France, Italy, Australia, and New Zealand Mangia et al AASLD Results: SVR12 ASTRAL-3 p <.1* 95 SVR12 (%) 2 264/ /275 SOF/VEL 12 Weeks SOF + RBV 24 Weeks *p-value for superiority of SOF/VEL compared with SOF+ RBV. Error bars represent 95% confidence intervals. 34 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 17
18 Results: SVR12 by Cirrhosis and Treatment History ASTRAL-3 SOF/VEL SOF + RBV SVR12 (%) No Yes No Yes Cirrhosis Treatment Naïve Treatment Experienced Error bars represent 95% confidence intervals. 35 C-Crest: Grazoprevir/MK-3682 (NS5B) + either elbasvir or MK-88 (NS5A) for 8 weeks SVR 45 2 GZR/EBR+RBV for 12 wks GZR/88/ mg for 8 GZR/88/ mg for 8 wks GT 1 GT 2 GT 3 wks Gane et al. AASLD 215 Abstract LB-15 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 18
19 QUARTZ-II/III: Paritaprevir/r/Ombitasvir and sofosbuvir with and without RBV in genotype 3 for /9 1/11 No RBV RBV Shafran et al. AASLD 215. Abstract LB-16 SURVEYOR-II Part 1 (GT3): Study Design SURVEYOR-II is an open-label, multicenter phase 2 trial evaluating the safety and efficacy of co-administered ABT-493 and ABT-53, at varying doses, ± ribavirin (RBV), in patients with HCV GT2 or GT3 infection Day 1 Week 12 PT Week 24 Treatment period Post-treatment (PT) period n=3 n=3 a n=31 n=3 ABT mg + ABT mg ABT mg + ABT mg ABT mg + ABT mg + RBV b ABT mg + ABT-53 mg ClinicalTrials.gov: NCT N=121. a Includes one patient who was incorrectly assigned to treatment in the GT2 cohort. b Daily dose of mg or 12 mg RBV dosed BID based on patient body weight being <75 kg or 75 kg. Kwo et al AASLD 215 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 19
20 SURVEYOR-II Part 1 (GT3): Per Protocol SVR12 Rates by Treatment* ABT ABT-53 3 mg + 12 mg *Excluding non-virologic failures. 2 mg + 12 mg 2 mg + 12 mg + RBV 2 mg + mg Kwo et al AASLD 215 Treatment Recommendations for Genotype 3 Population Recommended Regimen Duration Treatment naive Treatment naïve cirrhosis Treatment naïve Treatment naïve, IFN eligible Treatment experienced Treatment experienced non-cirrhosis Treatment ** not FDA experienced approved cirrhosis or SOF/RBV failure Sofosbuvir mg + Daclatasvir mg Sofosbuvir + daclatasvir mg with or without ribavirin Sofosbuvir mg + RBV -12 mg/day Sofosbuvir mg + pegifn + RBV -12 mg/day ** Sofosbuvir mg + pegifn + RBV -12 mg/day Sofosbuvir mg + Daclatasvir mg Sofosbuvir mg + daclatsavir mg plus RBV 24 weeks 24 weeks 24 weeks ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 2
21 TREATMENT OF GENOTYPE 4 Pearl-I GT4-Infected Treatment- Experienced Patients: ITT Efficacy Analysis Abbvie Technivie Package Insert July 29, 215 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 21
22 NEW THERAPIES ON THE HORIZON FOR GENOTYPE 4 44 C-Edge Naïve Study: SVR12 % 95% 92% 99% % % Patients, % 75% 5% 25% % 299/316 All Patients 144/ /131 18/18 GT1a GT1b GT4 8/1 GT6 Non-virologic failure Breakthrough 1 1 Relapse ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 22
23 Grazeprevir + Elbasvir for for treatment naïve and TE cirrhotic patients Treatment n/n SVR Duration Genotype 4 6/6 % n/n SVR SVR Genotype 4 TE 16/18 wks 4/4 % Pooled data from 6 studies Jacobson et al. AASLD 215 Abstract 42 Astral 1: Velpatasvir (NS5A) + SOF for 12 weeks- Genotype 2, 4, 5 and 6 97 SVR 2 14/14 116/116 41/41 34/35 GT 2 GT 4 GT 5 GT 6 Feld et al. AASLD 215 Abstract LB-2 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 23
24 Treatment Recommendations for Genotype 4 Population Recommended Regimen Duration Treatment naive Paritaprevir/ritonavir/ombitasvir + RBV -12 mg/day Ledipasvir/sofosbuvir Sofosbuvir mg + RBV -12 mg/day Sofosbuvir mg + pegifn + RBV -12 mg/day 24 weeks AASLD/IDSA treatment recommendation acessed 11/25/215s. Treatment Recommendations for Genotype 4 Population Recommended Regimen Duration IFN/RBV treatment experienced Paritaprevir/ritonavir/ombitasvir + RBV -12 mg/day Ledipasvir/sofosbuvir Sofosbuvir mg + RBV -12 mg/day Sofosbuvir mg + pegifn + RBV -12 mg/day ** 24 weeks AASLD/IDSA treatment recommendations accessed 11/25/215 ACG 215 Nashville Hepatitis School Copyright 215 American College of Gastroenterology 24
Hepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationCCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationAddressing Unmet Medical Needs in HCV Genotype 3
Addressing Unmet Medical Needs in HCV Genotype 3 Karen Doucette, MD, MSc (Epi), FRCPC Associate Professor, Division of Infectious Diseases, Department of Medicine University of Alberta Objectives Identify
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationHCV Update from AASLD 2016
HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking
More informationThe ASTRAL Program Abstracts LB-2, LB-12, 205, 209
The ASTRAL Program Abstracts LB-2, LB-12, 5, 9 The ASTRAL Program FDC 1. 2. 3. 4. 5. SOF Nucleotide polymerase inhibitor VEL NS5A inhibitor ASTRAL1 GT1, 2, 4 6 ASTRAL2 GT2 Jacobson IM, et al. N Engl J
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationDuncan Webster, BSc, BA, MA, MD, FRCPC
Moderator Duncan Webster, BSc, BA, MA, MD, FRCPC Internist, Infectious Disease Physician, Department of Medicine Medical Microbiologist, Department of Laboratory Medicine, Saint John Regional Hospital
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationHCV treatment options in clinical practice. Current treatment options for HCV-G4
HCV treatment options in clinical practice Current treatment options for HCV-G4 C. Triantos Gastroenterology Department University Hospital of Patras Conflicts of interest Speaker and research/travel grants
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationRapid Response from San Francisco: The Latest in the HCV Treatment Revolution
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationHCV Treatment in 2016
HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover
More informationStudy Design - GT 1 Retreatment
Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks Eric Lawitz, Steven Flamm, Jenny C. Yang, Phillip S. Pang, Yanni Zhu, Evguenia
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationManagement of HCV Tawesak Tanwandee
Management of HCV 2016 Tawesak Tanwandee Topics Burden of HCV in our countries Natural history and unmet need for HCV treatment Current treatment as for 2016 Conclusion Evolution from HCV infection to
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationHCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD
HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationO. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki
O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki Disclosures Advisory Board: Abbvie Pharmaceuticals Speaker: Gilead Sciences, Bristol-Myers Squibb Research
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationWonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited
Wonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited Harald Hofer Department of Internal Medicine III Division of Gastroenterology and Hepatology Medical
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationTreatment of Hepatitis C and Renal Disease
Treatment of Hepatitis C and Renal Disease David E. Bernstein, MD, FACG Vice Chair of Medicine for Clinical Trials Chief, Division of Hepatology and Director, Sandra Atlas Bass Center for Liver Diseases
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationDisclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.
Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of
More information